Health
Human recombinant soluble ACE2 successfully used in a patient with severe COVID-19 – News-Medical.Net
A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.
A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.
A pandemic spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for almost one million deaths due to COVID-19. Therefore, important insights into the viral pathophysiology may facilitate the quest for an eff…
-
Business20 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business19 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News16 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News15 hours agoQueen Street Mall to get a 3D digital billboard; Dutton dumps controversial plans to end flexible work; Measles alert for tourist hotspots